Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Bacteria’s Self-Defense Mechanisms Revealed

By BiotechDaily International staff writers
Posted on 24 Sep 2012
Print article
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Danish researchers have gleaned new insights into how bacteria control the amount of toxin in their cells. The new findings can ultimately lead to the development of novel forms of treatment for bacterial infections.

Many pathogenic bacteria are able to go into a dormant state by making persister cells that are not receptive to conventional antibiotics. This causes serious problems in the treatment of life-threatening disorders such as tuberculosis, where the presence of persister cells often leads to a resurgence of infection following medical treatment.

At the molecular level, the formation of persister cells is due to the presence of toxins that are produced by the bacteria themselves, and which enable them to enter the dormant state. During this hibernation period, the bacteria constantly regulate the amount of toxin at exactly the same level and thus maintain the dormant state.

In an article published online August 20, 2012, in the American scientific journal Structure, the researchers from the department of molecular biology and genetics, Aarhus University (Aarhus, Denmark), new findings that reveal the molecular particulars of the regulatory mechanism of toxins.

By isolating and crystallizing the toxin molecules and their molecular companions--the antitoxins--and by subsequently exposing the crystals to strong X-rays, the scientists gained unique insight into how bacteria control the amount of toxin in the cell.

The new findings can eventually lead to the development of completely new forms of treatment of bacterial infections that work at first by blocking toxin function and production, and consequently by using conventional antibiotics to fight the pathogenic bacteria.

Related Links:
Aarhus University


Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.